Market closedNon-fractional
Actinium Pharmaceuticals/ATNM
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Actinium Pharmaceuticals
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.
Ticker
ATNM
Sector
Healthcare
Trading on
AMEX
Industry
Biotechnology
Headquarters
New York, United States
Employees
49
Website
www.actiniumpharma.com
ATNM Metrics
BasicAdvanced
$235M
Market cap
-
P/E ratio
-$1.71
EPS
0.08
Beta
-
Dividend rate
Price and volume
Market cap
$235M
Beta
0.08
Financial strength
Current ratio
10.587
Quick ratio
10.424
Long term debt to equity
3.263
Total debt to equity
4.519
Management effectiveness
Return on assets (TTM)
-32.79%
Return on equity (TTM)
-91.92%
Valuation
Price to revenue (TTM)
2,648.341
Price to book
5.26
Price to tangible book (TTM)
5.26
Price to free cash flow (TTM)
-5.4
Growth
Revenue change (TTM)
-10.00%
Earnings per share change (TTM)
10.01%
3-year revenue growth (CAGR)
-49.31%
3-year earnings per share growth (CAGR)
6.13%
What the Analysts think about ATNM
Analyst Ratings
Majority rating from 7 analysts.
ATNM Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
NaN%
Net income
-$8.6M
-7.53%
Profit margin
0.00%
NaN%
ATNM Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.58
-$0.49
-$0.34
-$0.31
-
Expected
-$0.48
-$0.53
-$0.54
-$0.52
-$0.41
Surprise
20.83%
-7.84%
-37.04%
-40.38%
-
ATNM News
AllArticlesVideos
Actinium Announces FDA Clearance of Iomab-ACT Targeted Conditioning IND Application for Sickle Cell Disease Patients Undergoing Bone Marrow Transplant in Collaboration with Columbia University
PRNewsWire·2 days ago
Actinium Pharmaceuticals to Present at the 3rd Annual Targeted Radiopharmaceuticals Summit US
PRNewsWire·2 days ago
Biopharma Stocks Quest for Solutions for Acute Myeloid Leukemia (AML)
Newsfile Corp·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Actinium Pharmaceuticals stock?
Actinium Pharmaceuticals (ATNM) has a market cap of $235M as of July 27, 2024.
What is the P/E ratio for Actinium Pharmaceuticals stock?
The price to earnings (P/E) ratio for Actinium Pharmaceuticals (ATNM) stock is 0 as of July 27, 2024.
Does Actinium Pharmaceuticals stock pay dividends?
No, Actinium Pharmaceuticals (ATNM) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next Actinium Pharmaceuticals dividend payment date?
Actinium Pharmaceuticals (ATNM) stock does not pay dividends to its shareholders.
What is the beta indicator for Actinium Pharmaceuticals?
Actinium Pharmaceuticals (ATNM) has a beta rating of 0.08. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.
Buy or sell Actinium Pharmaceuticals stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.